Robert Bosch Krankenhaus GmbH

Futó vizsgálatok

• Toboroz

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· 2. fázis· Forrás

• Toboroz

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· 2. fázis· Forrás

• Még nem toboroz

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· 3. fázis· Forrás

• Toboroz

  PREFer

  NCT06916416· 2. fázis· Forrás

• Toboroz

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· 3. fázis· Forrás

• Toboroz

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· 3. fázis· Forrás

• Toboroz

  Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

  NCT06641414· 3. fázis· Forrás

• Toboroz

  Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

  NCT06201234· 2. fázis· Forrás

• Toboroz

  Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis

  2023-504724-25-00· 3. fázis· Forrás

• Fut, nem toboroz

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· 3. fázis· Forrás

• Toboroz

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· 3. fázis· Forrás

• Toboroz

  Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

  NCT05791409· 1/2. fázis· Forrás

• Toboroz

  Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

  NCT05904106· 2. fázis· Forrás

• Toboroz

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· 3. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· 3. fázis· Forrás

• Toboroz

  Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy

  NCT05551299· 4. fázis· Forrás

• Toboroz

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

  NCT05470595· 2. fázis· Forrás

• Toboroz

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  NCT04557462· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· 3. fázis· Forrás

• Fut, nem toboroz

  FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure

  NCT04495088· 3. fázis· Forrás

• Toboroz

  Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

  NCT04385290· 1/2. fázis· Forrás

• Fut, nem toboroz

  HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

  NCT01915615· Forrás

• Toboroz

  Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

  NCT03188874· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Akut mieloid leukémia (AML)3 toboroz
• Mielóma multiplex2 toboroz
• Áttétes emlőrák1 toboroz
• Elhízás1 toboroz
• Hodgkin-limfóma1 toboroz
• Idiopátiás tüdőfibrózis1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Krónikus vesebetegség1 toboroz
• Máj- és epeúti rák1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Sarlósejtes vérszegénység1 toboroz
• Szívelégtelenség1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Fut, nem toboroz

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· 3. fázis· Forrás

• Lezárult

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· 3. fázis· Forrás

• Lezárult

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· 3. fázis· Forrás

• Lezárult

  Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

  2024-511263-28-00· 4. fázis· Forrás

• Fut, nem toboroz

  A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

  NCT04486378· 2. fázis· Forrás

• Lezárult

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· 3. fázis· Forrás

• Lezárult

  A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

  2023-505035-12-00· 3. fázis· Forrás

• Lezárult

  Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

  NCT04330820· 1/2. fázis· Forrás

• Lezárult

  A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

  NCT04026412· 3. fázis· Forrás

• Lezárult

  MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse

  NCT03769532· 2. fázis· Forrás

• Toboroz

  Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

  NCT03571568· 1/2. fázis· Forrás

• Lezárult

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297· 3. fázis· Forrás

• Lezárult

  A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

  NCT03215706· 3. fázis· Forrás

• Lezárult

  HD21

  NCT02661503· 3. fázis· Forrás

• Lezárult

  Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

  NCT02504372· 3. fázis· Forrás

• Lezárult

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· 3. fázis· Forrás